Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Thioridazine (compound)

Name: Thioridazine
PubChem Compound ID: 5452
Description: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.
Molecular formula: C21H26N2S2
Molecular weight: 370.577 g/mol
Mellaril-S (TN); Sonapax hydrochloride; Malloryl; Mellerets; 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine; Phenothiazine, 10-[2-(1-methyl-2-piperidyl)ethyl]-2-(methylthio)-; Phenothiazine, 10-((1-methyl-2-piperidyl)ethyl)-2-(methylthio)-; 57129-06-3; Melleretten; Spectrum_001066.
show more »
Name: Thioridazine
Name (isomeric): DB00679
Drug Type: small molecule
Description: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.
Thoridazine Hydrochloride; Thioridazine Chloride; Thioridazine Hcl; Thioridazin; Thioridazine Hydrochloride
Brand: Ridazin, Mellerets, Malloryl, Mellaril, Sonapax, Sonapax Hydrochloride, Ridazine, Melleretten, Aldazine, Mellaril Hydrochloride, Thioridazine, Prolongatum, Mellerette, Metlaril, Tioridazin, Stalleril, Orsanil, Mallorol, Novoridazine, Mellarit, Mellaril-S, Melleril, Thioridazine Hcl Intensol, Meleril
Category: Phenothiazines, Dopamine Antagonists, Antipsychotic Agents, Antipsychotics
CAS number: 50-52-2
Indication: For the treatment of schizophrenia and generalized anxiety disorder.
Pharmacology: Thioridazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Thioridazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.
Mechanism of Action: Thioridazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; blocks alpha-adrenergic effect, depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
Absorption: 60%
Protein binding: 95%
Biotransformation: Hepatic
Half Life: 21-25 hours
Toxicity: LD50=956-1034 mg/kg (Orally in rats); Agitation, blurred vision, coma, confusion, constipation, difficulty breathing, dilated or constricted pupils, diminished flow of urine, dry mouth, dry skin, excessively high or low body temperature, extremely low blood pressure, fluid in the lungs, heart abnormalities, inability to urinate, intestinal blockage, nasal congestion, restlessness, sedation, seizures, shock
Affected organisms: Humans and other mammals
Drug interaction:
ErythromycinIncreased risk of cardiotoxicity and arrhythmias
GrepafloxacinIncreased risk of cardiotoxicity and arrhythmias
PentamidineIncreased risk of cardiotoxicity and arrhythmias
LevofloxacinIncreased risk of cardiotoxicity and arrhythmias
AmphetamineDecreased anorexic effect, may increase psychotic symptoms
show more »